Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Mycobacterium chelonae, an 'atypical' cause of an LVAD driveline infection.

Roest S, Bax HI, Verkaik NJ, Brugts JJ, Constantinescu AA, de Bakker CC, Birim O, Caliskan K, Manintveld OC.

Int J Infect Dis. 2020 Jan 8;92:127-129. doi: 10.1016/j.ijid.2020.01.002. [Epub ahead of print]

2.

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model.

Williams IP, Crescioli S, Sow HS, Bax HJ, Hobbs C, Ilieva KM, French E, Pellizzari G, Cox V, Josephs DH, Spicer JF, Karagiannis SN, Mele S.

MAbs. 2020 Jan-Dec;12(1):1685349. doi: 10.1080/19420862.2019.1685349.

3.

IgE Antibodies: From Structure to Function and Clinical Translation.

Sutton BJ, Davies AM, Bax HJ, Karagiannis SN.

Antibodies (Basel). 2019 Feb 22;8(1). pii: E19. doi: 10.3390/antib8010019. Review.

4.

Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy.

Wijting IE, Rokx C, Zillikens MC, Smits SA, de Vries-Sluijs TE, Schurink CA, Bax HI, van der Ende ME, van Gorp EC, Nouwen JL, Verbon A, Bierman WF, Rijnders BJ.

Int J STD AIDS. 2019 Oct;30(11):1042-1048. doi: 10.1177/0956462419848962. Epub 2019 Aug 20. No abstract available.

PMID:
31431155
5.

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.

Bax HI, de Vogel CP, Mouton JW, de Steenwinkel JEM.

J Antimicrob Chemother. 2019 Oct 1;74(10):2930-2933. doi: 10.1093/jac/dkz267.

PMID:
31236595
6.

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma.

Nakamura M, Bax HJ, Scotto D, Souri EA, Sollie S, Harris RJ, Hammar N, Walldius G, Winship A, Ghosh S, Montes A, Spicer JF, Van Hemelrijck M, Josephs DH, Lacy KE, Tsoka S, Karagiannis SN.

Oncoimmunology. 2019 Mar 28;8(6):e1593811. doi: 10.1080/2162402X.2019.1593811. eCollection 2019.

7.

AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.

Ilieva KM, Fazekas-Singer J, Bax HJ, Crescioli S, Montero-Morales L, Mele S, Sow HS, Stavraka C, Josephs DH, Spicer JF, Steinkellner H, Jensen-Jarolim E, Tutt ANJ, Karagiannis SN.

Allergy. 2019 Oct;74(10):1985-1989. doi: 10.1111/all.13818. Epub 2019 May 27. No abstract available.

8.

IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.

Pellizzari G, Hoskin C, Crescioli S, Mele S, Gotovina J, Chiaruttini G, Bianchini R, Ilieva K, Bax HJ, Papa S, Lacy KE, Jensen-Jarolim E, Tsoka S, Josephs DH, Spicer JF, Karagiannis SN.

EBioMedicine. 2019 May;43:67-81. doi: 10.1016/j.ebiom.2019.03.080. Epub 2019 Apr 5.

9.

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.

Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN.

Front Immunol. 2019 Mar 19;10:453. doi: 10.3389/fimmu.2019.00453. eCollection 2019. Review.

10.

AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.

Untersmayr E, Bax HJ, Bergmann C, Bianchini R, Cozen W, Gould HJ, Hartmann K, Josephs DH, Levi-Schaffer F, Penichet ML, O'Mahony L, Poli A, Redegeld FA, Roth-Walter F, Turner MC, Vangelista L, Karagiannis SN, Jensen-Jarolim E.

Allergy. 2019 Jun;74(6):1037-1051. doi: 10.1111/all.13718. Epub 2019 Mar 6.

11.

Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

Zweijpfenning SMH, van Groningen H, van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, Bax H, Andrejak C, Wener R, Rahman A, Kunst H, Lorent N, Brouwer MA, Hoefsloot W; NTM-NET.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801386. doi: 10.1183/13993003.01386-2018. Print 2018 Nov. No abstract available.

PMID:
30385602
12.

Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition.

Mitropoulou AN, Bowen H, Dodev TS, Davies AM, Bax HJ, Beavil RL, Beavil AJ, Gould HJ, James LK, Sutton BJ.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8707-E8716. doi: 10.1073/pnas.1806840115. Epub 2018 Aug 27.

13.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN.

Clin Cancer Res. 2018 Oct 15;24(20):5098-5111. doi: 10.1158/1078-0432.CCR-18-0652. Epub 2018 Aug 1.

14.

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI, Aarnoutse RE, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep.

15.

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

Josephs DH, Nakamura M, Bax HJ, Dodev TS, Muirhead G, Saul L, Karagiannis P, Ilieva KM, Crescioli S, Gazinska P, Woodman N, Lombardelli C, Kareemaghay S, Selkirk C, Lentfer H, Barton C, Canevari S, Figini M, Downes N, Dombrowicz D, Corrigan CJ, Nestle FO, Jones PS, Gould HJ, Blower PJ, Tsoka S, Spicer JF, Karagiannis SN.

Allergy. 2018 Dec;73(12):2328-2341. doi: 10.1111/all.13455. Epub 2018 Oct 8.

16.

Improving treatment outcome assessment in a mouse tuberculosis model.

Mourik BC, Svensson RJ, de Knegt GJ, Bax HI, Verbon A, Simonsson USH, de Steenwinkel JEM.

Sci Rep. 2018 Apr 9;8(1):5714. doi: 10.1038/s41598-018-24067-x.

17.

A multicentre verification study of the QuantiFERON®-TB Gold Plus assay.

Pieterman ED, Liqui Lung FG, Verbon A, Bax HI, Ang CW, Berkhout J, Blaauw G, Brandenburg A, van Burgel ND, Claessen A, van Dijk K, Heron M, Hooghiemstra M, Leussenkamp-Hummelink R, van Lochem E, van Loo IHM, Mulder B, Ott A, Pontesilli O, Reuwer A, Rombouts P, Saegeman V, Scholing M, Vainio S, de Steenwinkel JEM.

Tuberculosis (Edinb). 2018 Jan;108:136-142. doi: 10.1016/j.tube.2017.11.014. Epub 2017 Nov 28.

18.

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, Schurink C, Bax H, Derksen M, Andrinopoulou ER, van der Ende M, van Gorp E, Nouwen J, Verbon A, Bierman W, Rijnders B.

Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26.

PMID:
29107562
19.

BRAF inhibitors: resistance and the promise of combination treatments for melanoma.

Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, Pellizzari G, Wynne MD, Nakamura M, Hoffmann RM, Ilieva KM, Cheung A, Spicer JF, Papa S, Lacy KE, Karagiannis SN.

Oncotarget. 2017 Aug 3;8(44):78174-78192. doi: 10.18632/oncotarget.19836. eCollection 2017 Sep 29. Review.

20.

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Ilieva KM, Fazekas-Singer J, Achkova DY, Dodev TS, Mele S, Crescioli S, Bax HJ, Cheung A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs DH, Beavil AJ, Maher J, Spicer JF, Jensen-Jarolim E, Tutt AN, Karagiannis SN.

Front Immunol. 2017 Sep 11;8:1112. doi: 10.3389/fimmu.2017.01112. eCollection 2017.

21.

AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.

Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Dombrowicz D, Fiebiger E, Gould HJ, Irshad S, Janda J, Josephs DH, Levi-Schaffer F, O'Mahony L, Pellizzari G, Penichet ML, Redegeld F, Roth-Walter F, Singer J, Untersmayr E, Vangelista L, Karagiannis SN.

Allergy. 2018 Feb;73(2):328-340. doi: 10.1111/all.13311. Epub 2017 Oct 5. Review.

22.

IgE Trimers Drive SPE-7 Cytokinergic Activity.

Bax HJ, Bowen H, Beavil RL, Chung R, Ward M, Davies AM, Dodev TS, McDonnell JM, Beavil AJ, Sutton BJ, Gould HJ.

Sci Rep. 2017 Aug 15;7(1):8164. doi: 10.1038/s41598-017-08212-6.

23.

Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.

Mourik BC, de Knegt GJ, Verbon A, Mouton JW, Bax HI, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00696-17. doi: 10.1128/AAC.00696-17. Print 2017 Oct.

24.

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.

Bax HI, Bakker-Woudenberg IAJM, de Vogel CP, van der Meijden A, Verbon A, de Steenwinkel JEM.

Tuberculosis (Edinb). 2017 Jul;105:80-85. doi: 10.1016/j.tube.2017.04.010. Epub 2017 Apr 27.

PMID:
28610791
25.

Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.

Karagiannis SN, Josephs DH, Bax HJ, Spicer JF.

Cancer Res. 2017 Jun 1;77(11):2779-2783. doi: 10.1158/0008-5472.CAN-17-0428. Epub 2017 May 19. Review.

26.

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF, Karagiannis SN.

Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17.

27.

AllergoOncology - the impact of allergy in oncology: EAACI position paper.

Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, Karagiannis SN.

Allergy. 2017 Jun;72(6):866-887. doi: 10.1111/all.13119. Epub 2017 Jan 23. Review.

28.

Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN.

MAbs. 2016 Nov/Dec;8(8):1437-1455. Epub 2016 Aug 5. Review.

29.

Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.

Vigor K, Emerson J, Scott R, Cheek J, Barton C, Bax HJ, Josephs DH, Karagiannis SN, Spicer JF, Lentfer H.

Biotechnol Prog. 2016 Nov;32(6):1494-1502. doi: 10.1002/btpr.2359. Epub 2016 Oct 21.

PMID:
27604040
30.

Beta-glucan contamination of pharmaceutical products: How much should we accept?

Barton C, Vigor K, Scott R, Jones P, Lentfer H, Bax HJ, Josephs DH, Karagiannis SN, Spicer JF.

Cancer Immunol Immunother. 2016 Nov;65(11):1289-1301. Epub 2016 Jul 29. Review.

31.

IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.

Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Hernandez I, Josephs DH, Tosi I, Egbuniwe IU, Lombardi S, Crescioli S, Hobbs C, Villanova F, Cheung A, Geh JL, Healy C, Harries M, Sanz-Moreno V, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN.

Sci Rep. 2016 Jul 14;6:29736. doi: 10.1038/srep29736.

32.

Targeting folate receptor alpha for cancer treatment.

Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN.

Oncotarget. 2016 Aug 9;7(32):52553-52574. doi: 10.18632/oncotarget.9651. Review.

33.

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.

Bax HI, Bakker-Woudenberg IA, Ten Kate MT, Verbon A, de Steenwinkel JE.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2577-9. doi: 10.1128/AAC.02864-15. Print 2016 Apr.

34.

Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.

Josephs DH, Bax HJ, Lentfer H, Selkirk C, Spicer JF, Karagiannis SN.

Lancet. 2015 Feb 26;385 Suppl 1:S53. doi: 10.1016/S0140-6736(15)60368-3.

PMID:
26312875
35.

Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis.

Bax HI, de Steenwinkel JE, Ten Kate MT, van der Meijden A, Verbon A, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2015 Oct;70(10):2828-37. doi: 10.1093/jac/dkv194. Epub 2015 Jul 16.

PMID:
26183185
36.

Mechanism of the antigen-independent cytokinergic SPE-7 IgE activation of human mast cells in vitro.

Bax HJ, Bowen H, Dodev TS, Sutton BJ, Gould HJ.

Sci Rep. 2015 Apr 20;5:9538. doi: 10.1038/srep09538.

37.

Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class.

Dodev TS, Bowen H, Shamji MH, Bax HJ, Beavil AJ, McDonnell JM, Durham SR, Sutton BJ, Gould HJ, James LK.

Allergy. 2015 Jun;70(6):720-4. doi: 10.1111/all.12607. Epub 2015 Mar 28.

38.

Tumour-associated macrophage polarisation and re-education with immunotherapy.

Josephs DH, Bax HJ, Karagiannis SN.

Front Biosci (Elite Ed). 2015 Jan 1;7:293-308. Review.

PMID:
25553381
39.

[Lipotourism, not without risks: a complication of cosmetic surgery abroad].

Bax HI, van Ingen J, Dwarkasing RS, Verbon A.

Ned Tijdschr Geneeskd. 2014;158:A7926. Dutch.

PMID:
25248735
40.

A tool kit for rapid cloning and expression of recombinant antibodies.

Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, Bax HJ, Beavil R, Pang MO, Gould HJ, Karagiannis SN, Beavil AJ.

Sci Rep. 2014 Jul 30;4:5885. doi: 10.1038/srep05885.

41.

B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency.

Bax HI, Freeman AF, Anderson VL, Vesterhus P, Laerum D, Pittaluga S, Wilson WH, Holland SM.

J Clin Immunol. 2013 Aug;33(6):1062-6. doi: 10.1007/s10875-013-9907-0. Epub 2013 Jun 26.

42.

Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis.

Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, Chandrasekaran P, Rosen LB, Carvalho DS, Ding L, Vinh DC, Browne SK, Datta S, Milner JD, Kuhns DB, Long Priel DA, Sadat MA, Shiloh M, De Marco B, Alvares M, Gillman JW, Ramarathnam V, de la Morena M, Bezrodnik L, Moreira I, Uzel G, Johnson D, Spalding C, Zerbe CS, Wiley H, Greenberg DE, Hoover SE, Rosenzweig SD, Galgiani JN, Holland SM.

J Allergy Clin Immunol. 2013 Jun;131(6):1624-34. doi: 10.1016/j.jaci.2013.01.052. Epub 2013 Mar 28.

43.

Interferon alpha treatment of patients with impaired interferon gamma signaling.

Bax HI, Freeman AF, Ding L, Hsu AP, Marciano B, Kristosturyan E, Jancel T, Spalding C, Pechacek J, Olivier KN, Barnhart LA, Boris L, Frein C, Claypool RJ, Anderson V, Zerbe CS, Holland SM, Sampaio EP.

J Clin Immunol. 2013 Jul;33(5):991-1001. doi: 10.1007/s10875-013-9882-5. Epub 2013 Mar 20.

44.

Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations.

Rice LV, Bax HJ, Russell LJ, Barrett VJ, Walton SE, Deakin AM, Thomson SA, Lucas F, Solari R, House D, Begg M.

Eur J Pharmacol. 2013 Mar 15;704(1-3):49-57. doi: 10.1016/j.ejphar.2013.02.022. Epub 2013 Feb 27.

PMID:
23454522
45.

Cytokinergic IgE Action in Mast Cell Activation.

Bax HJ, Keeble AH, Gould HJ.

Front Immunol. 2012 Aug 6;3:229. doi: 10.3389/fimmu.2012.00229. eCollection 2012.

46.

Mapping of the CD23 binding site on immunoglobulin E (IgE) and allosteric control of the IgE-Fc epsilonRI interaction.

Borthakur S, Hibbert RG, Pang MO, Yahya N, Bax HJ, Kao MW, Cooper AM, Beavil AJ, Sutton BJ, Gould HJ, McDonnell JM.

J Biol Chem. 2012 Sep 7;287(37):31457-61. doi: 10.1074/jbc.C112.397059. Epub 2012 Jul 19.

47.

A novel STAT1 mutation associated with disseminated mycobacterial disease.

Sampaio EP, Bax HI, Hsu AP, Kristosturyan E, Pechacek J, Chandrasekaran P, Paulson ML, Dias DL, Spalding C, Uzel G, Ding L, McFarland E, Holland SM.

J Clin Immunol. 2012 Aug;32(4):681-689. doi: 10.1007/s10875-012-9659-2. Epub 2012 Feb 29.

48.

New insights in diagnosing Schistosoma myelopathy.

de Jongste AH, Tilanus AM, Bax H, Willems MH, van der Feltz M, van Hellemond JJ.

J Infect. 2010 Mar;60(3):244-7. doi: 10.1016/j.jinf.2009.12.002. Epub 2010 Jan 19.

PMID:
20004686
49.

Brucellosis, an uncommon and frequently delayed diagnosis.

Bax HI, van Veelen ML, Gyssens IC, Rietveld AP.

Neth J Med. 2007 Oct;65(9):352-5.

50.

Internet quality indicators for health professional agencies and associations.

Courtney KL, Alexander GL, Pack B, Bax H, Adams-Leander S, Holcomb M.

AMIA Annu Symp Proc. 2005:931.

Supplemental Content

Support Center